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ABSTRACT
The sharing of clinical trial data and biomarker data 
sets among the scientific community, whether the data 
originates from pharmaceutical companies or academic 
institutions, is of critical importance to enable the 
development of new and improved cancer immunotherapy 
modalities. Through data sharing, a better understanding 
of current therapies in terms of their efficacy, safety 
and biomarker data profiles can be achieved. However, 
the sharing of these data sets involves a number of 
stakeholder groups including patients, researchers, private 
industry, scientific journals and professional societies. 
Each of these stakeholder groups has differing interests 
in the use and sharing of clinical trial and biomarker 
data, and the conflicts caused by these differing interests 
represent significant obstacles to effective, widespread 
sharing of data. Thus, the Society for Immunotherapy of 
Cancer (SITC) Biomarkers Committee convened to identify 
the current barriers to biomarker data sharing in immuno- 
oncology (IO) and to help in establishing professional 
standards for the responsible sharing of clinical trial data. 
The conclusions of the committee are described in two 
position papers: Volume I—conceptual challenges and 
Volume II—practical challenges, the first of which is 
presented in this manuscript. Additionally, the committee 
suggests actions by key stakeholders in the field (including 
organizations and professional societies) as the best path 
forward, encouraging the cultural shift needed to ensure 
responsible data sharing in the IO research setting.
THE UNMET NEED FOR DATA SHARING IN 
IMMUNO-ONCOLOGY
Advances in cancer immunotherapy have 
significantly improved life expectancy, quality 
of life and overall survival for some patients 
with cancer. However, only a relatively small 
percentage of patients receiving immuno- 
oncology (IO) treatments currently achieve 
durable responses and lasting disease- free 
survival, and the mechanisms and patient 
attributes underlying immune responsiveness 
and resistance have yet to be fully under-
stood.1 Given the high costs and potential 
side effects associated with these therapies, 
it is crucial to identify the subsets of patients 
who will clinically benefit from immuno-
therapy. In addition, understanding the 
biological basis of mechanisms of resistance 
to IO treatments is essential for identifying 
new therapeutic approaches, including the 
design of rational therapeutic combinations.2
It is now widely accepted that in the field 
of IO, the conventional single biomarker 
approach has failed to have a substantial 
impact in improving treatment efficacy or 
in informing the next generation of IO ther-
apeutics due to the broad heterogeneity of 
malignant diseases and limited sizes of patient 
subgroups providing data.3 4 In addition, the 
complex and dynamic nature of the tumor 
microenvironment, together with variability 
in host genetic background and environ-
mental factors, makes the identification and 
subsequent validation of biomarkers from 
single trials a nearly impossible endeavor. 
Since the determinants of cancer immune 
responsiveness are multifactorial (including 
genetic makeup of the patient, tumor 
genomic instability, epigenetic adaptation, 
and external modifiers such as the micro-
biome, concomitant medications, comorbid-
ities, etc), collection and analysis of ‘big data’ 
sets for biomarker discovery are becoming 
the norm in the IO clinical research field.5–7 
Therefore, converging efforts in biomarker 
identification and validation using existing 
datasets and combined patient popula-
tions with properly collected clinical and 
biomarker data (ie, meta- analyses) are greatly 
needed to guide patient selection, treatment 
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decisions, and advances in new therapy developments in 
IO.
To date, the development and validation of new 
biomarkers for IO has been limited by the fragmenta-
tion of clinical research efforts, often conducted in a 
drug- centric way, statistically designed to determine effi-
cacy or safety end points instead of biomarker validation 
endpoints, and have used investigator/sponsor preferred 
non- standardized technology platforms, with different 
levels of analytic validation applied to relatively small data 
sets (usually with low numbers of responders). The combi-
nation of all of these factors results in a lack of intrinsic 
robustness and underpowered statistical outputs, making 
most observations hypothesis- generating, at best.
In this context, harmonized clinical and biomarker 
data sharing can leverage, unify, and maximize sample 
sizes; enhance biomarker identification, validation, 
and impact on clinical decision making; and provide a 
launching pad to accelerate new discoveries. This can be 
achieved by using existing and completed studies, poten-
tially avoiding future duplicative trials (unless there is a 
clear mechanistic reason that a drug within an existing 
class would have better efficacy in a different study popu-
lation and/or indication). The success and benefit of data 
sharing will include facilitating the identification and vali-
dation of standardized biomarkers through meta- analysis 
and enabling maximal scientific knowledge and benefits 
to be gained from the efforts of clinical trial participants 
and investigators. However, the enabling of this paradigm 
shift in the field of clinical data sharing and IO biomarker 
discovery and validation will require a concerted effort 
from all involved stakeholders.
Current challenges to data sharing can be divided into 
two major categories:
 ► Conceptual Challenges: Key stakeholders may have 
conflicting interests (both financial and academic) 
and ethical and regulatory restrictions, which need 
to be taken into consideration and balanced for data 
sharing to become the norm in clinical research.8–12
 ► Practical Challenges: Effective data sharing requires 
the improvement and/or standardization of the 
systems and protocols governing clinical research, 
including minimal information required for data 
alignment, standardized statistical approaches, data 
management infrastructure, technology for data 
acquisition and analysis, workforce training, and equi-
table distribution of the costs of research.12–14
The Society for Immunotherapy of Cancer (SITC) 
Biomarkers Committee formed the Clinical and 
Biomarkers Data Sharing Subcommittee to discuss 
challenges from both of these categories. Conceptual 
challenges and related possible mitigation steps to data 
sharing in IO are described in detail in this manuscript, 
while the practical challenges and recommended mitiga-
tion strategies are discussed in the companion manuscript 
‘The SITC clinical and biomarkers data sharing resource 
document: Volume II—practical challenges.’ Impor-
tantly, these challenges need to be addressed in parallel 
and in a holistic way in order to make data sharing in IO 
the standard in clinical research.
An unprecedented example of the power of open data 
sharing has come from the COVID-19 pandemic. In 
January 2020, just days after isolation of the SARS- CoV-2 
virus, its genome sequence was published and shared with 
the scientific community.15 Since then, characterization 
of the virus and associated disease has continued, with 
additional isolates sequenced and data openly shared, 
allowing researchers to monitor and track the progres-
sion of the pandemic. For example, NextStrain has been 
tracking and updating information on the progression 
and changes observed in the viral genome.16 Sequences 
can be uploaded and shared through the Global Initiative 
on Sharing all Influenza Data.17 Epidemiology data are 
being made available by the Johns Hopkins University of 
Medicine,18 Worldometers,19 the nCoV-2019 data working 
group,20 Our World in Data,21 and the World Health 
Organization (WHO)22 dashboards on the coronavirus 
disease pandemic, which keep ongoing statistics on the 
spread of the virus, and appraise health officials and the 
world of the situation, therefore, allowing for critical 
movement of resources to impacted regions. The WHO 
has acted to ensure open access to scientific publications, 
creating a database of 77103 citations on the COVID-19 
pandemic and SARS- CoV-2 as of October 7 2020.23 Impor-
tantly for the concerns of oncologists, the COVID-19 and 
Cancer Consortium was rapidly formed to share data 
on cancer patients with COVID-19 among many institu-
tions.24 25 Additionally, many journals and professional 
societies, including SITC, have encouraged and enabled 
open access to articles related to COVID-19 research.26 
As a consequence of efforts like those discussed above, 
the rapid availability of data such as epitope sequences 
including the binding site of SARS- CoV-2 spike protein 
to its entry receptor, angiotensin converting enzyme 2 
(ACE2), is propelling the generation of diagnostic tests, 
vaccines, and antibody therapeutics.27 28 Additionally, 
data sharing during the COVID-19 pandemic has been 
facilitated through the availability of pre- print services 
such as medRxiv and bioRxiv; however, the sheer number 
of preprint articles in COVID-19- related research has 
prompted calls to parse this non- peer- reviewed literature 
and grade articles by quality.29 30
CONCEPTUAL CHALLENGES TO DATA SHARING IN IO
Ethical considerations: patient privacy and ‘big data’ 
challenges
Even though most informed consent processes approved 
by ethics committees have embedded clauses allowing the 
future nonprofit use of deidentified data, patients’ will-
ingness to share their de- identified data does come with 
specific requirements in order to protect their privacy, 
choices, and needs for information regarding the use of 
their data. Efforts to balance patients’ right to data protec-
tion/confidentiality against the need to promote medical 
science advances through clinical research has been a 
 on N
ovem
ber 1, 2020 by guest. P
rotected by copyright.
http://jitc.bm
j.com
/
J Im
m
unother C
ancer: first published as 10.1136/jitc-2020-001389 on 30 O
ctober 2020. D
ow
nloaded from
 
3Rutella S, et al. J Immunother Cancer 2020;8:e001389. doi:10.1136/jitc-2020-001389
Open access
topic of significant debate in recent years.31 To ensure 
ethical and regulatory compliance and the sustainability 
and success of data sharing initiatives in cancer research, 
appropriate legislation and guidelines need to be imple-
mented. Joint multi- stakeholder agreements and efforts 
need to be pursued to foster cultural (ie, conceptual) and 
technological (ie, practical) adaptation or discovery- led 
changes that will enable patients’ preferences regarding 
sharing of their own health data to be respected.
In the US, the Health Insurance Portability and 
Accountability Act (HIPAA) is a federal law that governs 
the use and disclosure of personal health information by 
covered entities, defined as health plans, healthcare clear-
inghouses, and healthcare providers. The general rule 
is that personal health information cannot be disclosed 
without the patient’s authorization. Three primary 
measures protect patient privacy and confidentiality: 
(1) informed consent, (2) study review and approval by 
Institutional Review Boards (IRBs) and Research Ethics 
Committees (RECs), and (3) data use limited to deiden-
tified information.
The intent behind informed consent regulations is to 
ensure that, before providing their consent, participants 
are fully aware of the study they are volunteering for, and 
that they have been given a clear and accurate account of 
the potential risks and expected benefits of the study. In 
relation to data sharing, it is important that the informed 
consent form includes appropriate language explaining 
the information collected including data generated from 
integrative genetic/genomic assays on the patients’ speci-
mens and how this data will be stored and used, including 
the potential for being shared outside the boundaries of 
the specific study in which they were collected, such as for 
integrative meta- analyses.
IRBs and RECs are tasked with reviewing, revising, 
and approving clinical investigation protocols involving 
humans with the goal of protecting research participants 
and ensuring that they are treated ethically in the course 
of their participation in studies.32–34 These committees 
play close attention to the informed consent process and 
should provide guidance for investigators and informed 
consent templates for participants to enable respon-
sible data sharing. In addition, IRBs should influence 
the responsible sharing of individual participant data 
by adding considerations for data sharing plans when 
assessing the benefits and risks of clinical trials in IO. 
Moreover, consistent policies within and between insti-
tutions are needed so that investigators, IRBs, and other 
institutional officials know what level of protection they 
can promise to participants and participants can make 
decisions based on accurate and truthful information.
Data deidentification by removing individually identifi-
able health information from data sets is another measure 
aimed to protect patient privacy. However, the increase 
of research involving ‘big data,’ particularly in IO, may 
impair efforts to maintain patient privacy. Because big data 
can contain family history and genetic information, abso-
lute data deidentification can be challenging.35 36 Indeed, 
one of the main ethical challenges and risks posed to clin-
ical trial participants that has been identified regarding 
data sharing is the possible reidentification of previously 
deidentified data. The standard data protections used 
to anonymize or deidentify patient- representative data 
were devised prior to current deep sequencing, multiplex 
technologies, and multiomics platforms that produce 
higher resolution, more detailed information on patient 
samples.37
The National Science Foundation funded an initia-
tive to establish the Council for Big Data, Ethics, and 
Society, which discusses the importance of maintaining 
ethical standards in the relatively new field of big data 
analysis. The council has also noted that big data often 
resides outside of existing systems designed to ensure that 
research is ethical, and noted several unique issues associ-
ated with big data research. These unique issues include: 
non- physical harm resulting from research (harm by 
enabling surveillance or discrimination), unpredictable 
uses of data in the future (beyond the scope of the orig-
inal study), and the possibility that individually ‘safe’ 
data sets may be combined to generate data capable of 
causing harm to participants.38 The council also made a 
series of recommendations regarding policy, pedagogy, 
and networking.
Disease advocacy organizations share many of the same 
concerns, roles, and responsibilities as those of other non- 
profit funders and clinical trial sponsors with regard to 
data sharing. Whether through direct financial support 
(either alone or as part of a funding syndicate) or other 
forms of assistance (eg, participant recruitment or clinical 
research networks), disease advocacy organizations make 
significant contributions to the development and execu-
tion of clinical trials. These efforts give these organiza-
tions an opportunity to influence policies and strategies 
to encourage responsible sharing of clinical trial data.39
Data ownership: protection of intellectual property
Historically, the culture surrounding clinical research in 
industry has not encouraged the proactive sharing of clin-
ical trial data, including biomarker data. There are several 
reasons for this reluctance. Investors and industry are 
mostly driven by business models that require the gener-
ation of revenue. Therefore, data gathered with industry 
sponsorship or in support of marketing applications is 
often considered commercially confidential and compet-
itively advantageous, representing a significant resource 
investment by the sponsoring organization. As a conse-
quence, new findings that could be competitively advan-
tageous are commonly considered protected intellectual 
property (IP), which impedes data sharing. Unwillingness 
to relinquish control of data for fear of misuse and the 
potential for incidental findings that require regulatory 
application resubmission have been additional concerns 
among the pharmaceutical industry.
Over the last 5 years, data sharing within the pharma-
ceutical industry has evolved from being virtually non- 
existent to being a landscape in which most companies 
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have participated in one form or another, both for the 
public good and for the opportunity to uncover new 
insights and add value to existing data. This has been 
particularly true during the current COVID-19 pandemic 
response, and for the field of IO, where access to ‘big’ 
datasets is crucial. In general, access to, and collabora-
tion with, top scientists and a perceived trustworthiness 
of academic involvement in data analysis is an important 
factor in the sharing of clinical trial data by pharmaceu-
tical companies.40
The Foundation for the National Institutes of Health 
(FNIH) has launched and coordinated the Partnership 
for Accelerating Cancer Therapies (PACT) program, 
aimed at building an oncology clinical study database 
with state- of- the art study design, technology implemen-
tation, and pipelines for databases, bioinformatics, and 
biostatistics, as well as planning for future public open 
access to the database. This program is truly a partnership 
effort contributed to by the US government, industry, 
biotech, biopharma, and academia. It lays the foundation 
for clinical data sharing in principle and in practice in 
the future and promotes the sharing of existing data for 
retrospective exploratory biomarker discovery. However, 
for the pharmaceutical sector to truly benefit, data collab-
oration needs to be incorporated into business as usual, 
rather than remaining the domain of special projects.
Participant motivations: formal recognition and career 
incentives
In most academic research communities, publications 
are the primary currency. Promotions, grants, and 
recruitment policies are often based on publication track- 
records. The demands and offers of publication outlets, 
therefore, have an impact on the individual research-
er’s data sharing disposition. Because academic success 
depends on published outputs, and because only a small 
fraction of the accrued data is published in the primary 
report of a clinical trial, many academics have been reti-
cent to share data. A 2018 European survey showed that 
more than 30% of researchers do not routinely share 
scientific data.41 Fear that competitors may publish novel 
findings and/or misuse the original data represents an 
additional hurdle to broad data sharing. This understand-
able response to a lack of incentives and protection is in 
line with other situations in the biomedical field, such as 
the publication of negative data.42 Thus, there is a cultural 
gap and a lack of governing framework that needs to be 
addressed by educating the scientific community and by 
policy/guideline development. Data sharing in academia 
is a multidimensional effort that includes a diverse set 
of stakeholders, entities, and individual interests. In the 
fast moving and fast publishing modern era of biomed-
ical sciences, unless sufficient recognition is paid to the 
intellectual and physical efforts involved in designing, 
accruing, and curating comprehensive and usable clinical 
trial data sets slated for sharing with the greater medical 
community, individual investigators will continue to work 
in silos, and forgo the data sharing process that is essen-
tial to continued advancement.
Integral steps toward remedying this issue are for 
governing frameworks to be built with data protection 
and data sharing in mind, and for clinical investigators 
to recognize the value of data sharing and the accompa-
nying infrastructure. This could be promoted by inviting 
collaboration and co- authorship on publications resulting 
from the use of existing data in new research. In addition, 
funders can accelerate this process by providing tangible 
rewards to clinical investigators for data sharing activities. 
Research institutions and universities should also make 
sharing of clinical trial data a consideration in promotion 
of faculty members and assessment of programs. Finally, 
training for data science and collaboration with quantita-
tive scientists to facilitate sharing and analysis of clinical 
trial data should also be emphasized.
Journals: impetus and platform for data sharing
Biomedical journals can play a central role in champi-
oning and providing recognition for data sharing as well. 
Currently, the academic h- index of success is calculated 
based on the set of the scientist’s most cited papers and 
the number of citations that they have received in other 
publications.43 Authors actively participating in data 
sharing should also be scored and recognized accordingly 
for advancing the field. With fewer restrictions in publica-
tion lengths and upper limits on numbers of references 
resulting from electronic/online journals (in contrast to 
past hard copy issues), journals should be responsible 
for ascertaining that all primary data set contributors be 
properly cited to increase their individual professional 
scores, enhancing academic or industrial recognition, 
and thereby sustaining the motivation to share data. More 
importantly, journals can take the lead in promoting data 
sharing norms.
While a statement recommending data sharing has 
been accepted as a step in the right direction by the Inter-
national Committee of Medical Journal Editors initiative, 
response was starkly divided, and prominent research 
funders including the Wellcome Trust, National Insti-
tutes of Health (NIH), Medical Research Council (MRC), 
Cancer Research UK, and Bill & Melinda Gates Founda-
tion declared that the mandates are still vague and open 
for interpretation.44
Nevertheless, many higher impact journals already 
mandate data set deposition to repositories (eg, the Gene 
Expression Omnibus or the database of Genotypes and 
Phenotypes) at the time of manuscript submission, in 
addition to mandates on explicit clarity on algorithms 
used for data analyses reported. Though repositories 
provide templates and guidelines for correct summary 
reporting for gene expression and DNA sequencing data 
set submissions, there is a lack of common clinical data 
elements from patients. Such a set of common elements 
would enhance the usability and harmonization of data 
sets for meta- analyses investigating predictive biomarkers 
for immunotherapies, and could be established by 
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journal- linked repositories. A notable set of meta- studies 
demonstrated that journals that require data sharing by 
authors for peer review and publication typically have 
significantly higher impact factors, suggesting that jour-
nals may also benefit from mandating and streamlining 
standards (eg, providing guidelines and templates) that 
ensure sustainable data sharing.45 46
Additionally, preprint servers, including bioRxiv and 
medRxiv, operated by Cold Spring Harbor Laboratory, 
could accelerate the pace of science and expedite data 
sharing with a large audience long before research 
data are published in peer- reviewed journals, while also 
ensuring that ideas are not ‘stolen’ and that a record of 
priority is established. This avenue of data sharing has 
been used frequently, more recently during the COVID-19 
pandemic, motivated by the need to share emerging 
relevant information in real time with the medical and 
scientific community. Major research funders, including 
the MRC, the NIH, and the Howard Hughes Medical 
Institute, have recently begun to encourage the citation 
of pre- prints and urge grant applicants to cite pre- prints 
in their funding proposals. However, it should be made 
clear that pre- prints reporting the results of clinical trials 
have not been peer- reviewed, and that they should there-
fore not be used to guide clinical decision making by 
other researchers.
Further, to create a responsible medium for biomarker 
data sharing, societies such as SITC and journals (including 
the Journal for Immunotherapy of Cancer (JITC)) can initiate 
and support an independent body that promotes good 
practices and standardized data stewardship to ensure 
that biomarker data are fairly and consistently presented; 
valid based on sample size and methodology; and acces-
sible, interpretable, reusable, and interoperable as per 
the ‘Findable, Accessible, Interpretable and Reusable’ 
guiding principles for scientific data management and 
stewardship.47
Professional societies: hubs for data sharing and biomarker 
development
At the intersection of improvements in patient outcomes 
and the advancement of IO research are professional 
societies. Organizations including SITC, the American 
Association for Cancer Research (AACR), the American 
Association of Immunologists (AAI), the American Society 
of Clinical Oncology (ASCO), the American Society of 
Hematology (ASH), and the American Society for Trans-
plantation and Cellular Therapy (ASTCT), among several 
others, represent the collective interests of thousands of 
physicians, research scientists, advanced practitioners, 
nurses, biostatisticians, and patient advocates.
With the historical strength of professional societies as 
a guide, these organizations have great leverage in the 
pursuit of large- scale collaboration and data sharing. As an 
example, ASH is creating infrastructure and is designing a 
process for sharing genomic and clinical data on multiple 
myeloma called the ASH Research Collaborative (ASH 
RC), an initiative that could serve as a model for other 
diseases. The ASH RC Data Hub will also host industry 
or government datasets and will be able to accommo-
date data in different formats, including patient- reported 
instruments and manual chart abstraction.48
Another example, the AACR Project Genomics 
Evidence Neoplasia Information Exchange (GENIE) is 
a publicly accessible international cancer registry assem-
bled through data sharing.49 The registry links high- 
quality next- generation cancer genomic sequencing data 
with clinical outcomes obtained during routine medical 
practice from nearly every patient with cancer treated 
at 19 of the leading oncology institutions in the world, 
including individuals with rare cancers. The AACR Project 
GENIE therefore potentially provides the statistical power 
required to inform clinical decision making and to foster 
novel clinical and translational research.
The leverage possessed by professional societies could 
also be used to aid in setting standards or in establishing 
commonplace norms for data sharing within the immu-
notherapy space. For example, societies can allocate 
resources to convene workshops and establish commit-
tees of experts that can develop standard operating 
procedures, set standards for research and clinical prac-
tice within the field, and publish white papers advocating 
for particular research priorities or policy positions. For 
example, the SITC Biomarkers Committee has held work-
shops and generated outputs aimed at providing a plat-
form for representatives to discuss the advantages and 
challenges of data sharing from federal, academic, and 
industrial perspectives.50 The Biomarkers Committee has 
also drawn attention to the importance of standardized 
and validated assays, a crucial component of successful 
data sharing.51–53 Furthermore, the society’s open- access 
journal, JITC, has also been on the leading edge of 
important developments in the field since its inception 
through the publication of original research within its 
dedicated Immunotherapy Biomarkers section.
Societies may also provide funding for grants or 
programs that enable or enhance data sharing, both in 
the clinical and basic and translational research settings. 
These funding initiatives can play a vital role in unifying 
ongoing projects and preventing duplication of efforts. 
One such example was the establishment of a concept 
called TimIOs that would function as an honest broker for 
data set amalgamation between biotech companies that 
was established through SITC’s Sparkathon Program.50 
The eventual goal of the project is to identify biomarkers 
that differentiate between patients with tumors that are 
likely to respond strongly or weakly to anti- PD-1 therapies.
A more ambitious, but potentially more rewarding 
proposal would be for societies to initiate or promote the 
development of an immunotherapy outcomes registry. 
The proposed registry network of IO data, contributed on 
a volunteer basis, could be initiated in principle by lever-
aging the political capital of medical professional soci-
eties through policy and advocacy efforts toward a larger 
national or international initiative. An example that could 
serve as a model registry program for society- led efforts is 
 on N
ovem
ber 1, 2020 by guest. P
rotected by copyright.
http://jitc.bm
j.com
/
J Im
m
unother C
ancer: first published as 10.1136/jitc-2020-001389 on 30 O
ctober 2020. D
ow
nloaded from
 
6 Rutella S, et al. J Immunother Cancer 2020;8:e001389. doi:10.1136/jitc-2020-001389
Open access 
the FNIH PACT, which is engaged in efforts on behalf of 
several academic institutions, biotech and pharmaceutical 
companies, and the federal government and is involved 
in standardizing immunotherapy assays with the Cancer 
Immune Monitoring and Analysis Centers and in housing 
this data from privately or NIH- funded studies through a 
cloud based, central data repository as part of the Cancer 
Immunologic Data Commons Network. However, the 
FNIH PACT effort does not include a larger mechanism 
to globally collect biomarker and outcomes data for those 
oncology patients treated with immuno- therapeutics in 
‘real- world’ settings,50 which is an area of need that societies 
could potentially address with their own registry programs.
Professional society initiatives aimed at clinical data 
sharing have proven successful. In one of the most promi-
nent examples, the world of hematopoietic stem cell trans-
plantation offers guidance. In 1970, the International 
Bone Marrow Transplant Registry (IBMTR) was founded 
as a division of the American College of Surgeons/
National Institutes of Health Organ Transplant Registry.54 
By 1976, with the dissolution of the American College of 
Surgeons Organ Transplant Registry, the IBMTR became 
a standalone agency based in Milwaukee, Wisconsin and 
supported by the US Department of Health, Education 
and Welfare. In the years since that time the IBMTR 
merged with the National Bone Marrow Donor Registry 
in 2004 and formed one comprehensive program, the 
Center for International Blood & Marrow Transplant 
Research, which has continued to accrue invaluable data 
related to hematopoietic stem cell transplantation.55 
These data have played a pivotal role in shaping the devel-
opment of hematopoietic stem cell transplants.
Another example of a federal- level program that could 
serve as an effective model for future society programs 
is The Cancer Genome Atlas (TCGA), a successful data 
sharing initiative that has generated and compiled 
comprehensive genomic, transcriptomic, epigenomic, 
and proteomic data from bulk tumor samples across 33 
human malignancies.56 57 Through this approach and 
collaborative effort, six immune subtypes of solid tumors 
of prognostic significance have been identified.56 All 
data and results are intended to serve as a resource for 
future studies and can be freely accessed at the National 
Cancer Institute Genomic Data Commons, which houses 
data not only from TCGA but from several other cancer 
genomic projects, and through the Cancer Research 
Institute iAtlas portal, which provides interactive visual-
ization of immune response in tumors. An in- depth atlas 
of the immune microenvironment of human tumors has 
been developed in clear cell renal cell carcinoma and 
early lung cancer, representing an invaluable tool for the 
rational design of targeted therapies as well as combina-
tion immunotherapy clinical trials.58 59 Additionally, the 
Human Protein Atlas is another example of successful 
data sharing. The program was initiated in 2003 in 
Sweden and aims to map all the human proteins in cells, 
tissues and organs using integrative- omics technologies. 
The online platform provides access to the distribution of 
the proteins across tissues, organs, the subcellular local-
ization of proteins, and potential prognostic impacts of 
protein expression on cancer patient survival.
CONCLUSIONS
In summary, IO data sharing is an idea that is not only 
beneficial in concept, but one that promises to be a 
powerful tool in combating cancer once made routine. 
Joint efforts from diverse stakeholders described in this 
paper are required to champion, adopt, and foster a 
culture of data sharing with realistic goals. Data sharing 
also requires entities that can provide management and 
oversight to ensure the protection of patient privacy, 
IP for funding organizations, and primary publication 
rights. These entities should also work to ensure the 
quality, integrity, and completeness of shared informa-
tion, and that protocols governing data access and reuse 
are ethical, fair, and transparent. Data sharing will help 
break down silos that can inadvertently lead to the dupli-
cation of work and wasted research dollars. It is not only 
a possibility, but only a matter of time until the cycle of 
data silo- ing will be broken. In the future, clinical study 
data will not be boxed away after the initial study- focused 
analysis, but reused to accelerate the pace of discovery in 
the field. As we take stock of those stakeholders who hold 
the potential to shift our culture of competition into one 
of collaboration, we see the role that professional soci-
eties such as SITC have played, and can continue to act as 
champions for such change.
Worldwide, research policy makers support the acces-
sibility of research data. This can be seen in the US with 
efforts by the NIH and in Europe, with the European 
Union’s Horizon 2020 Program.60–63 In order to develop 
consequential policies for data sharing, policy- makers need 
to understand and address the perspectives of all involved 
parties. We hope that the framework that we present in 
this paper will encourage a better understanding of the 
prevailing issues and provide insights into the underlying 
dynamics of academic and Pharma data sharing.
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